Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human PALB2 Antibodies:
anti-Mouse (Murine) PALB2 Antibodies:
anti-Rat (Rattus) PALB2 Antibodies:
Go to our pre-filtered search.
Human Polyclonal PALB2 Primary Antibody for ICC, IF - ABIN253057
Brough, Bajrami, Vatcheva, Natrajan, Reis-Filho, Lord, Ashworth: APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer. in The EMBO journal 2012
Show all 2 Pubmed References
Human Polyclonal PALB2 Primary Antibody for IHC, IP - ABIN253058
Martrat, Maxwell, Tominaga, Porta-de-la-Riva, Bonifaci, Gómez-Baldó, Bogliolo, Lázaro, Blanco, Brunet, Aguilar, Fernández-Rodríguez, Seal, Renwick, Rahman, Kühl, Neveling, Schindler, Ramírez et al.: Exploring the link between MORF4L1 and risk of breast cancer. ... in Breast cancer research : BCR 2011
The results of the present study suggest that mutations in the PALB2 gene may be particularly relevant to breast cancer susceptibility in the Jamaican population.
We identified two PALB2 mutations that are founder alleles in Italian families, one of which is, independently, also a founder mutation in American-Hispanic breast cancers.
Our results indicate that the PALB2 exon 13 duplication is a pathogenic variant. The presence of the PALB2 duplication in the proband affected with high-grade serous ovarian cancer suggests that PALB2 might be associated with a predisposition to ovarian cancer.
We showed that the mutation frequency of RAD51C (show RAD51C Antibodies) in Japanese familial breast cancer cases was similar to that in Western countries and that the prevalence of deleterious mutation of PALB2 was possibly lower. Furthermore, our results suggested that BRIP1 (show MRPL36 Antibodies) mutation frequency in Japan might differ from that in Western countries
Study have shown that mutations in BRCA1, BRCA2 (show BRCA2 Antibodies), and PALB2 account for more than 10 % of breast cancer in Trinidad and Tobago. 25 different mutations identified; of these, four mutations were seen in two patients each.
Germline mutations in the PALB2 gene were observed at a frequency of approximately 1.5% in Polish breast and/or ovarian cancer patients
Prevalence of germline PALB2 mutations among women with epithelial ovarian cancer in Ontario
inherited pathogenic variants in PALB2 were associated with high risks of breast cancer
Findings establish L35P as the first pathogenic missense mutation in PALB2 and directly demonstrate the requirement of the PALB2-BRCA1 interaction for breast cancer suppression.
In this paper, we describe an extension to the BOADICEA model to incorporate the effects of intermediate risk variants for breast cancer, specifically loss of function mutations in the three genes for which the evidence for association is clearest and the risk estimates most precise: PALB2, CHEK2 (show CHEK2 Antibodies) and ATM (show ATM Antibodies)
we describe a genetic approach to examine the functional significance of the interaction between BRCA2 (show BRCA2 Antibodies) and PALB2 by generating a knock-in mouse model of Brca2 (show BRCA2 Antibodies) carrying a single amino acid change (Gly25Arg, Brca2G25R) that disrupts this interaction. In addition, we have combined Brca2G25R homozygosity as well as hemizygosity with Palb2 and Trp53 (show TP53 Antibodies) heterozygosity .
results underscore the in vivo importance of the PALB2-BRCA1 complex formation in DSB repair and male meiosis
Palb2 synergizes with Trp53 (show TP53 Antibodies) to suppress mammary tumor formation in a model of inherited breast cancer.
A key function for PALB2 is to interact with and to build up appropriate communication between BRCA1 (show BRCA1 Antibodies) and BRCA2 (show BRCA2 Antibodies).
This gene encodes a protein that may function in tumor suppression. This protein binds to and colocalizes with the breast cancer 2 early onset protein (BRCA2) in nuclear foci and likely permits the stable intranuclear localization and accumulation of BRCA2.
partner and localizer of BRCA2
, Fanconi N
, Fanconi anemia
, complementation group N
, partner and localizer of BRCA2-like